Search research articles
Contact Us
Filters
Showing results (101-110 of 137) with videos related to
Page
of 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
International Journal of Clinical Oncology
|
March 30, 2021
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, et al.
JCO Global Oncology
|
April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study
Bhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
European Thyroid Journal
|
January 5, 2024
Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer
Janice Ser Huey Tan, Timothy Kwang Yong Tay, Enya Hui Wen Ong, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 10, 2012
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Keith C Bible, Vera J Suman, Michael E Menefee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Nature Medicine
|
September 19, 2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma
Daniel S W Tan, Fui Teen Chong, Hui Sun Leong, et al.
Translational Lung Cancer Research
|
October 17, 2022
Comprehensive analysis of T cell receptor repertoire in patients with <i>KRAS</i> mutant non-small cell lung cancer
Yadong Wang, Ling Peng, Ming Zhao, et al.
Nature Communications
|
May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
Stephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 137) with videos related to
Sort By:
Page
of 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
International Journal of Clinical Oncology
|
March 30, 2021
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, et al.
JCO Global Oncology
|
April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study
Bhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
European Thyroid Journal
|
January 5, 2024
Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer
Janice Ser Huey Tan, Timothy Kwang Yong Tay, Enya Hui Wen Ong, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 10, 2012
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Keith C Bible, Vera J Suman, Michael E Menefee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Nature Medicine
|
September 19, 2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma
Daniel S W Tan, Fui Teen Chong, Hui Sun Leong, et al.
Translational Lung Cancer Research
|
October 17, 2022
Comprehensive analysis of T cell receptor repertoire in patients with <i>KRAS</i> mutant non-small cell lung cancer
Yadong Wang, Ling Peng, Ming Zhao, et al.
Nature Communications
|
May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
Stephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.
Page
of 14